中恆集團(600252.SH):正式簽訂廣西奧奇麗股份有限公司重整協議
格隆匯 8 月 14日丨中恆集團(600252.SH)公佈,2020年8月13日,公司與奧奇麗公司管理人簽訂了《廣西奧奇麗股份有限公司重整協議》。
若此次重整順利完成,公司將持有奧奇麗公司全資子公司田七化粧品公司不低於55%的股權,將對田七化粧品公司實現控制,並納入公司合併報表範圍。田七化粧品公司在未來的生產經營過程中可能會受到市場風險、安全環保風險、管理風險、業績不能實現預期風險等多種因素影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.